<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00601770</url>
  </required_header>
  <id_info>
    <org_study_id>IC41-202</org_study_id>
    <nct_id>NCT00601770</nct_id>
  </id_info>
  <brief_title>Virological Response Study of the HCV Vaccine IC41</brief_title>
  <official_title>Open-label, Multicenter Trial With IC41, a Therapeutic HCV Vaccine in Patients With Chronic HCV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to investigate the virological (HCV-RNA) responses following biweekly
      immunization with IC41.

      Treatment phase 14 weeks, total study duration including follow-up period 38 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCV-RNA 2 weeks after end of treatment</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological assays and Safety</measure>
    <time_frame>until study end</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>IC41</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 injections of 4 x 0.125mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IC41</intervention_name>
    <description>injection</description>
    <arm_group_label>IC41</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained prior to study entry

          -  Patients with chronic hepatitis C; genotype 1

          -  Treatment naive patients

          -  Male and Female, 18 to 55 years

          -  Presence of HLA-A2 marker

          -  Mentally healthy

          -  No clinically relevant pathological findings in any of the investigations at screening

          -  Treatment naive patients with chronic Hepatitis C of genotype 1

        Exclusion Criteria:

          -  Positive results in HIV, HBsAg and HAV-Ag (IgM)

          -  Other causes of chronic hepatitis

          -  History of autoimmune diseases

          -  Previous vaccination with any prophylactic or therapeutic Hepatitis C vaccine (in a
             clinical study)

          -  Active or passive vaccination 4 weeks before and during the entire study period

          -  Decompensated liver disease

          -  History of severe hypersensitivity reactions and anaphylaxis

          -  Known allergic reactions to one of the components of the vaccine and Imiquimod cream

          -  Clinically significant diseases which, in the opinion of the Investigator, might lead
             to frequent hospitalization/medical attendance

          -  Malignancies

          -  Immunosuppressive therapy

          -  Pregnancy, lactation or breast-feeding

          -  Unwillingness to practice appropriate contraception

          -  Participation in another study with an investigational drug within 1 month prior to
             enrolment and the entire study period

          -  Patients, who in the opinion of the Investigator, might not be able to comply with the
             study protocol (e.g.: Drug addiction, alcoholism)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonja Ernsthofer, Mag</last_name>
    <role>Study Director</role>
    <affiliation>Valneva Austria GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prof. Dr. Ulrich Spengler</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Michael Manns</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Granzyna Cholewinska-Szymanska</name>
      <address>
        <city>Warzawa</city>
        <zip>01201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Andrzej Gladszy</name>
      <address>
        <city>Wroclaw</city>
        <zip>51149</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Mircea Diculescu</name>
      <address>
        <city>Bucharest</city>
        <zip>11461</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Adriana Motoc</name>
      <address>
        <city>Bucharest</city>
        <zip>30303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Adriana Hristea</name>
      <address>
        <city>Bucharest</city>
        <zip>72204</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Carol Stanciu</name>
      <address>
        <city>Iasi</city>
        <zip>700111</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

